MAPT and Alzheimer disease: In fact, the MCI-AD group showed lower levels for amyloid β-42, and higher levels for t-Tau and p-Tau; also, MCI-AD group showed lower scores for MMSE, and RBANS, and higher scores for CDR and FAQ.